Source link : https://newshealth.biz/health-news/trial-analysis-characterizes-sclc-disease-progression/
Durvalumab consolidation therapy reduced the rate of extrathoracic metastases vs placebo and prolonged the time to progression or death due to any metastases in patients with limited-stage small-cell lung cancer (LS-SCLC), according to an exploratory analysis of data from the pivotal phase 3 ADRIATIC study. Extrathoracic metastases occurred in 18.2% and 25.2% of patients in […]
The post Trial Analysis Characterizes SCLC Disease Progression first appeared on News Health.
Author : News Health
Publish date : 2025-04-03 12:13:00
Copyright for syndicated content belongs to the linked Source.
in Health